TB Alliance: Putting science to work for a faster TB cure

Follow Us:

Advisory Boards

The TB Alliance established a Scientific Advisory Committee to provide invaluable scientific guidance.

The Scientific Advisory Committee provides technical expertise on drug research, development, manufacturing, and distribution, as well as other medical and scientific issues. It consists of fourteen scientific experts from a wide range of relevant disciplines, including:

  • Drug Discovery: genomics, microbiology, molecular biology, medicinal chemistry and pharmacology;
  • Drug development: medicinal chemistry, preclinical development, formulation and manufacturing experts;
  • Clinical expertise: internal medicine, infectious diseases, and clinical trials;
  • Clinical trials in TB-endemic countries;
  • Epidemiology;
  • Pharmaceutical and biotechnology industries; and
  • Statistics

Members of the Scientific Advisory Committee are selected for three-year terms. To address myriad scientific and technical needs, the Chair has the flexibility to invite scientists to serve as ad hoc members for limited periods of time, or on a project-by-project basis.

Members

Dr. Karen Bush Indiana University
Dr. Shing Chang (Formerly) Drugs for Neglected Disease Initiative
Prof. Stewart Cole Ecole Polytechnique Fédérale de Lausanne
Dr. Michael Dunne Durata Therapeutics, Inc
Dr. Mark Goldberger Abbott Laboratories
Dr. Stefan Kaufmann Max Planck Institute for Infection-Biology
Dr. Dale J. Kempf Abbott Laboratories
Dr. G. Lynn Marks GlaxoSmithKline
Prof. Lester A. Mitscher University of Kansas
Dr. Valerie Mizrahi Institute of Infectious Disease and Molecular Medicine
Dr. Paul Reider Princeton University
Dr. Jack Reynolds Anabios
Dr. Eric Rubin (Chair) Harvard School of Public Health
Dr. Christine Sizemore National Institute of Allergy & Infectious Diseases
Dr. Jeffrey A. Staffa Consilium, LLC